Ribbon Biolabs GmbH

Based in Vienna, Austria, and founded in 2018, by co-founders Harold de Vladar and Wladimir Labeikovsky, Ribbon Biolabs GmbH, aka Ribbon Biolabs operates as a developer of automated synthesis of long DNA molecules to enable innovation in biotechnology. In January 2022, Ribbon Biolabs GmbH raised EUR 18 million in a Series A funding led by new investors Hadean Ventures, Helicase Venture, Lansdowne Partners, IST cube, and tecnet equity. The company provides an in-house synthesis platform InfiniSynth, a technology involving machine learning and robotic automation for the enzymatic assembly of long DNA molecules. Ribbon Biolabs also offer FullGenes, which produces and delivers a synthetic linear double-stranded DNA molecule according to a customer specification and uses combinatorial optimization algorithms to guide the automated enzymatic assembly of DNA.

The platform applies robotic adaptive control in a sequence-specific manner to ensure the highest accuracy of the synthetic DNA. The company's services offer deoxyribonucleic acid to create genomes, high-throughput libraries, innovative deoxyribonucleic acid-based products, store data, and more. In addition, the company provides researchers and companies with the flexibility to focus on libraries of deoxyribonucleic acids with lengths up to base pairs.